Last reviewed · How we verify
One IM injection Lenti-HPV-07
One IM injection Lenti-HPV-07 is a Small molecule drug developed by Theravectys S.A.. It is currently in Phase 1 development.
At a glance
| Generic name | One IM injection Lenti-HPV-07 |
|---|---|
| Sponsor | Theravectys S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- One IM injection Lenti-HPV-07 CI brief — competitive landscape report
- One IM injection Lenti-HPV-07 updates RSS · CI watch RSS
- Theravectys S.A. portfolio CI
Frequently asked questions about One IM injection Lenti-HPV-07
What is One IM injection Lenti-HPV-07?
One IM injection Lenti-HPV-07 is a Small molecule drug developed by Theravectys S.A..
Who makes One IM injection Lenti-HPV-07?
One IM injection Lenti-HPV-07 is developed by Theravectys S.A. (see full Theravectys S.A. pipeline at /company/theravectys-s-a).
What development phase is One IM injection Lenti-HPV-07 in?
One IM injection Lenti-HPV-07 is in Phase 1.
Related
- Manufacturer: Theravectys S.A. — full pipeline
- Compare: One IM injection Lenti-HPV-07 vs similar drugs
- Pricing: One IM injection Lenti-HPV-07 cost, discount & access